City
Epaper

Eli Lilly, Cipla enter in partnership to enhance access to Lilly's key diabetes products

By ANI | Updated: October 4, 2021 15:00 IST

Pharmaceutical firm Eli Lilly and Cipla entered into a strategic partnership in India to enhance access to Lilly's key diabetes products on Monday.

Open in App

Pharmaceutical firm Eli Lilly and Cipla entered into a strategic partnership in India to enhance access to Lilly's key diabetes products on Monday.

Eli Lilly and Company, India Pvt. Ltd (referred as "Lilly") headquartered in Gurgaon, is a wholly-owned subsidiary of Eli Lilly and Company, a global biopharmaceutical company headquartered in Indianapolis, USA.

As a part of this agreement, Lilly will transfer its rights in India to sell, promote and distribute two Lilly Diabetes products such as Humalog and TrulicityTM to Cipla, subject to all regulatory approvals.

Commenting on the partnership, Luca Visini, Managing Director India Subcontinent, Lilly India, said, "For more than 145 years, Lilly has been committed to uniting caring with discovery to create medicines that make life better for people around the world."

"We have remained true to that promise. Developing strategic partnerships to adopt different operating models is key to enabling Lilly's global efforts to make innovative medicines available to more people in India and around the world," Visini said.

"Today, we are proud to be announcing our partnership with Cipla, which pending full regulatory approvals will hold the rights to sell, market, and distribute select Lilly Diabetes portfolio products. Cipla has a strong local footprint and is well established to expand access to those medicines around India," he said.

Dr Vikas Gupta, Head, India Prescription Business, Cipla Ltd. said, "Enhancing access to high-quality treatments is central to our purpose of 'Caring for Life'. Lilly's in-depth scientific knowledge and core purpose of providing patients with access to innovative products are aligned with Cipla's goals."

"We are pleased to collaborate and build onto our existing partnership with Lilly India towards bringing innovative diabetes medications to India. Diabetes continues to be our key focus and this deal further strengthens our steadfast commitment to addressing the unmet needs of diabetes patients through a comprehensive portfolio of offerings in this space," Gupta said.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Eli Lilly and CompanyLuca visiniGurgaonIndianapolisCipla limitedCiplaCipla ltd.
Open in App

Related Stories

NationalGurugram Shocker: Air Hostess Sexually Assaulted While On Ventilator By Hospital Staff

InternationalIndianapolis: Over 135,000 Without Power After Tornado Hits Carmel; Visuals Emerge

NationalRajpal Yadav Passes Away: SP Leader Akhilesh Yadav's Uncle Dies at Hospital in Gurgaon

NationalDelhi-Gurgaon Highway Traffic Update: Vehicular Jam on National Highway 8 as Scooty Catches Fire (Watch Video)

NationalHaryana Air Pollution: No Physical Classes in Rohtak, Jhajjar, Gurgaon and Sonipat; AQI at 452

National Realted Stories

NationalBihar's first pedestrian subway nears completion in Patna: Minister

NationalGovt land freed from encroachment in largest demolition drive near Chandola lake in Ahmedabad

NationalRajasthan Police issue alert against cyber crime on pretext of Char Dham Yatra

NationalNDA, Grand Alliance spar over 'caste census credit' in Bihar; JD-U leader slams Oppn

NationalDisplaying 'Hindu terror', 'Gayab' posters made Cong leaders heroes in Pakistan: Union Minister